Step 1 of 2

#1 Improving Clinical Evidence Generation With Real-World Data in Lung Cancer With EGFR Uncommon Mutations: Experience, Evidence and Excellence From K Hospital
Thanh Ha Vu​

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#2 Survival Outcomes of First-Line EGFR TKIs in Advanced NSCLC Patients With Poor Prognostic Features: A Comparative Subgroup Analysis
Ching-Yi Chen

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#3 Optimal Consideration for Maximal Clinical Benefit via Sequencing Treatment: Experience From Yonsei Cancer Center
Sun Min Lim​

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#4 The Surgical Resection of the Primary Tumor Increases Survival in Patients With EGFR-Mutant Advanced NSCLC
Po-Lan Su

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#5 Optimal Treatment in Advanced EGFR-Mutant NSCLC With CNS Metastasis: How to Combat Brain Challenge in CGMH
Chi-Hsien Huang​

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#6 Optimal Treatment in Advanced EGFR-Mutant NSCLC: Experience From HCMC Oncology Hospital
Khoi Tuan Nguyen

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10

#7 How Sequential Treatment Fits Into Current Practice in EGFR-Mutant NSCLC in Taiwan: Experience From VGH-TC
Yen-Hsiang Huang​

12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10
12345678910
1
2
3
4
5
6
7
8
9
10